Community-Acquired Pneumonia.
Thomas M File, Julio A Ramirez
https://pubmed.ncbi.nlm.nih.gov/37585629/Actively Recruiting
Led by Shanghai General Hospital, China · Updated on 2026-04-23
800
Participants Needed
1
Research Sites
24 weeks
Total Duration
Researchers are studying antimicrobial resistance AMR in patients with severe and mild pneumonia by analyzing their microbiomes using metagenomics. The study aims to understand the microbial communities present, the number of resistance genes carried by pathogens, and the genetic diversity of key pathogens from 2019 to 2025. This observational study collects data from multiple hospitals in China to improve pneumonia diagnosis and treatment strategies. Participants diagnosed with severe or mild pneumonia are identified based on established guidelines from the American Thoracic Society, Infectious Diseases Society of America, and British Thoracic Society. Clinical examination samples such as nasopharyngeal or oropharyngeal swabs, sputum, blood, lung tissue, and bronchoalveolar lavage fluid are collected. Advanced sequencing techniques, including next-generation sequencing on the Illumina Novaseq 6000 platform, are used to analyze the microbiome, viruses, bacteria, fungi, and antimicrobial resistance genes. Throughout the study period from 2019 to 2025, researchers analyze microbiome composition, alpha and beta diversity, and the presence of bacterial resistance genes. They use bioinformatics tools to filter and classify sequencing data, identify pathogens, and assess genetic diversity. Outcome measures focus on the microbiomes role in pneumonia, and findings will help characterize resistance patterns. The study runs until September 2026, with continuous recruitment and data collection.
CONDITIONS
Monitoring of Antimicrobial Resistance Based on Metagenomics Analyses in Pneumonia Patients
M
Mei Kang, MPH
X
Xue Tian, Master
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Shanghai General Hospital, China
Lead Sponsor
Wuxi People's Hospital Affiliated to Nanjing Medical University
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 6 years (2019 to 2025)
Participants diagnosed with severe or mild pneumonia are observed to monitor antimicrobial resistance and microbiome composition through analysis of biological samples collected during routine clinical care.
Biological samples collected as part of clinical care during the study period
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Thomas M File, Julio A Ramirez
https://pubmed.ncbi.nlm.nih.gov/37585629/Yong-Zhen Zhang, Yan-Mei Chen, Wen Wang...
https://pubmed.ncbi.nlm.nih.gov/31100994/Joshua P Metlay, Grant W Waterer, Ann C Long...
https://pubmed.ncbi.nlm.nih.gov/31573350/Charles Y Chiu, Steven A Miller
https://pubmed.ncbi.nlm.nih.gov/30918369/Na Li, Qingqing Cai, Qing Miao...
https://pubmed.ncbi.nlm.nih.gov/33614906/Fan Wu, Su Zhao, Bin Yu...
https://pubmed.ncbi.nlm.nih.gov/32015508/Shingo Suzuki, Takaaki Horinouchi, Chikara Furusawa
https://pubmed.ncbi.nlm.nih.gov/25517437/Antimicrobial Resistance Collaborators
https://pubmed.ncbi.nlm.nih.gov/35065702/Brian P Alcock, Amogelang R Raphenya, Tammy T Y Lau...
https://pubmed.ncbi.nlm.nih.gov/31665441/Mang Shi, Su Zhao, Bin Yu...
https://pubmed.ncbi.nlm.nih.gov/35176118/Shanghai General Hospital, China
Lead Sponsor
Wuxi People's Hospital Affiliated to Nanjing Medical University
Collaborating Sponsor